Anticancer activity of Cabozantinib and Temozolomide in cell lines derived from lung carcinoid and pancreatic neuroendocrine tumors

#4146

Introduction: Limited therapeutic options are available for patients with advanced neuroendocrine neoplasms (NENs). Cabozantinib (CBZ), a tyrosine kinase inhibitor including c-MET pathway, and Temozolomide (TMZ), an alkylating agent enhancing the anti-angiogenic effect of CBZ, are emerging as promising treatments in NENs.

Aim(s): The aim of this work was to investigate the anticancer activity of CBZ, TMZ and their combination in cell lines derived from human lung carcinoid (H727) and pancreatic neuroendocrine cell lines (BON-1).

Materials and methods: H727 and BON-1 cell lines were treated with increasing doses of CBZ (2.5uM and 5uM) or TMZ (10uM, 50uM, 100uM, 250uM and 500uM) to calculate the IC50 value. The inhibitory effect of CBZ and TMZ were determined by Trypan blue cell viability assay at 24, 48 and 72 hours of treatment.

Conference:

Presenting Author:

Authors: Tornesello M, Starita N, Clemente O, Cerasuolo A, Bracigliano A,

Keywords: cabozantinib, temozolomide, neuroendocrine tumor, cell lines, in vitro study,